RelB is activated by the non-canonical NF-iB pathway, which is crucial for immunity by establishing lymphoid organogenesis and B-cell and dendritic cell (DC) maturation. To elucidate the mechanism of the RelBmediated immune cell maturation, a precise understanding of the relationship between cell maturation and RelB expression and activation at the single-cell level is required. Therefore, we generated knock-in mice expressing a fusion protein between RelB and fluorescent protein (RelB-Venus) Venus/Venus mice as a useful tool to analyse the dynamic regulation of the non-canonical NF-iB pathway.
RelB is activated by the non-canonical NF-iB pathway, which is crucial for immunity by establishing lymphoid organogenesis and B-cell and dendritic cell (DC) maturation. To elucidate the mechanism of the RelBmediated immune cell maturation, a precise understanding of the relationship between cell maturation and RelB expression and activation at the single-cell level is required. Therefore, we generated knock-in mice expressing a fusion protein between RelB and fluorescent protein (RelB-Venus) from the Relb locus. The Relb Venus/Venus mice developed without any abnormalities observed in the Relb / mice, allowing us to monitor RelB-Venus expression and nuclear localization as RelB expression and activation. Relb Venus/Venus DC analyses revealed that DCs consist of RelB , RelB low and RelB high populations. The RelB high population, which included mature DCs with projections, displayed RelB nuclear localization, whereas RelB in the RelB low population was in the cytoplasm. Although both the RelB low and RelB populations barely showed projections, MHC II and co-stimulatory molecule expression were higher in the RelB low than in the RelB splenic conventional DCs. Taken together, our results identify the RelB low population as a possible novel intermediate maturation stage of cDCs and the Relb Venus/Venus mice as a useful tool to analyse the dynamic regulation of the non-canonical NF-iB pathway.
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The nuclear factor-kB (NF-kB) family of transcription factors regulates the expression of genes that are necessary for inflammation, immunity and cell survival (1) . The family is composed of RelA, RelB and c-Rel as well as the precursor and processed products of the NFKB1 (p105/p50) and NFKB2 (p100/p52) genes. Although they are able to form homodimers or heterodimers in various combinations, the main complexes are the p50/RelA and the p52/RelB heterodimers (24) . In unstimulated cells, the p50/RelA is sequestered in the cytoplasm by IkBa, a member of the inhibitor of NF-kB (IkB) family, which masks the nuclear localization signal of the p50/RelA. Various cytokines, such as tumour necrosis factor (TNF)-a and interleukin (IL)-1, and bacterial products activate the canonical NF-kB pathway, which plays a critical role in inflammatory cytokine expression and apoptosis inhibition (5) . Binding of these ligands to the corresponding receptors results in the activation of the IkB kinase (IKK) complex composed of two catalytic subunits, IKKa and IKKb, and a regulatory subunit, NF-kB essential modulator (NEMO). IKK then phosphorylates IkBa on critical serine residues and targets it for K48 polyubiquitination. As a consequence, the ubiquitinated IkBa is degraded by the proteasome, which in turn allows the p50/RelA complex to enter the nucleus and activate target genes (6) . In contrast, p52/RelB is first localized in the cytoplasm as a heterodimer of RelB with p100, a precursor of p52, which is composed of p52 at the N-terminus and the IkB-like domain at the C-terminus, which can block RelB nuclear translocation. p52/RelB nuclear translocation is induced in the non-canonical pathway, which is activated by stimulation of lymphotoxin-b receptor (LTbR), CD40, receptor activator of NF-kB (RANK), fibroblast growth factor-inducible 14 (Fn14), or B cell activating factor belonging to TNF family receptor (BAFFR). This pathway involves IKKa homodimer activation, which then phosphorylates the p100 C-terminal domain and targets it for proteasome-dependent processing to generate p52. This allows the p52/RelB complex to enter the nucleus and activate target genes (7, 8) .
Although the canonical pathway is activated by numerous stimuli and has diverse functions, the noncanonical pathway responds to only a subset of the TNF receptor superfamily. However, several lines of evidence indicate that the non-canonical pathway is crucial for the establishment of specific but essential immune system responses, including lymphoid organogenesis, B-cell survival and maturation and dendritic cell differentiation and maturation (911), whose molecular mechanisms, nevertheless, are not fully understood. To elucidate the mechanisms, a precise understanding of the relationship between cell differentiation, maturation and non-canonical pathway activation at the single-cell level is required. Therefore, we generated a knock-in mouse expressing a RelB-Venus fusion protein from the endogenous Relb genomic locus, which allowed us to monitor expression and nuclear accumulation of RelB, a crucial transcription factor of the non-canonical pathway, at the single-cell level.
Materials and Methods
Mice Venus cDNA (obtained from A. Miyawaki, RIKEN, Japan) followed by FLAG-epitope nucleotides were inserted just upstream of the translational termination codon in the exon 12. A diphtheria toxin A (DT-A) gene was used for negative selection of clones with random integration of the targeting vector. A floxed neo selection marker for ES cell selection was introduced into intron 11. The targeting vector was transfected into 129S6/SvEvTac embryonic stem (ES) cells and homologous recombinant clones were selected and identified with Southern blot analysis. By breeding chimeric male mice with C57BL/6 female mice, Relb Targeted/+ mice, which retained a loxP-flanked neomycin-resistant cassette (PGK-Neo), were obtained. The Relb Targeted/+ mice were mated with CAG-Cre transgenic mice (obtained from J. Miyazaki, Osaka University, Japan) (Sakai and Miyazaki, 1997) to delete the PGK-neo cassette to generate Relb Venus/+ mice. The Relb Venus/+ mice were crossed to generate Relb-Venus knock-in (Relb Venus/Venus ) mice. Relb / mice were purchased from The Jackson Laboratory. These male and female mice were used at 6-10 weeks of age for DC or histological analyses. All of the mice were maintained under specific pathogenfree conditions and were handled in accordance with the Guidelines for Animal Experiments of the Institute of Medical Science, The University of Tokyo (Tokyo, Japan).
Antibodies
Anti-RelB (4922), anti-p100/p52 (4882) and anti-IkBa (9242) antibodies were purchased from Cell Signaling Technology. Anti-PARP1 (sc-25780) and anti-RelA (sc-8008) antibodies were purchased from Santa Cruz Biotechnology. Anti-tubulin (CP06) antibody was purchased from Calbiochem. Purified antimouse CD16/32 antibody was purchased from BioLegend. APC-conjugated anti-mouse CD45RA (14.8) antibody was purchased from Miltenyi Biotec. PE-conjugated anti-mouse CD11c (HL3), APC/ Cy7-conjugated rat anti-mouse CD45 (30-F11) and Alexa Fluor 647-conjugated rat anti-mouse CD8a (53-6.7) antibodies were purchased from BD. PE/Cy7-conjugated anti-mouse MHC II (M5/ 114.15.2) and CD103 (2E7) antibodies were purchased from BioLegend. APC/Cy7-conjugated anti-mouse CD45 (30-F11) and CD86 (GL-1) antibodies were purchased from BioLegend.
Plasmids
A cDNA encoding simian virus (SV) 40 large T antigen was generated by PCR with appropriate primers and inserted into the pMXs retroviral vector, which was obtained from T. Kitamura (University of Tokyo, Japan).
Cell culture
Embryonic fibroblasts, which derived from Relb-Venus knock-in mice (RelB-Venus MEFs), were immortalized with the SV40 large T antigen. The MEFs were maintained in low glucose Dulbecco's modified Eagle's medium (DMEM) (Wako, 041-29775) supplemented with 10% FBS (Gibco, 26140-079). Plat-E cells (obtained from T. Kitamura) were maintained in high glucose DMEM (Wako, 043-30085) containing 10% FBS. Recombinant murine TNFa (PEPROTECH, 400-14) was used at a final concentration of 10 ng/ml. To stimulate the LTbR, a 10:1 mix of the 4H8 WH2 (Adipogen, AG-20B-0008) and 3C8 (eBiosciences, 16-5671-82) monoclonal antibodies was used.
Immunoblotting MEFs were suspended in hypotonic buffer (10 mM HEPES at pH7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, protease inhibitor cocktail and 0.5% NP-40) and incubated on ice for 20 min followed by the centrifugation at 2000Â g for 5 min at 4 C. The supernatants were stored as the cytoplasmic fraction. The pellets were considered to be the nuclear fraction and were stored after an additional washing with a hypotonic buffer. Both of the fractions were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDSPAGE) and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore). The membranes were incubated with the appropriate primary antibodies. Immunoreactive proteins were visualized with anti-rabbit or anti-mouse IgG conjugated to horseradish peroxidase (Amersham Biosciences), followed by processing with an enhanced chemiluminescence (ECL) detection system (Amersham Biosciences).
Cell isolation from thymus and spleen
The method of DC extraction and analyses from the thymi or spleens were previously described (12) . The organs were chopped and digested with 1 mg/ml collagenase D (Roche, 11088866001) and 100 mg/ml DNase I (Sigma-Aldrich). To disrupt the DC-T cell complexes, EDTA was added and the samples were mixed continuously for 5 min. The light density cells were collected. For the spleens, erythrocytes were lysed with lysis buffer for 5 min and washed. The cells were incubated with PE-conjugated anti-mouse CD11c antibody and then mixed with anti-PE microbeads (Miltenyi Biotec, 130-048-801). The CD11c + cells were purified by positive selection using a MACS Separation LS Columns (Miltenyi Biotec, 130-042-401) and MidiMACS Separator (Miltenyi Biotec, 130-042-302). After isolation, the cells were passed through a nylon mesh (Sanplatec, 12569).
Cell isolation from the colon
The colons were chopped, added to an EDTA-containing solution and shaken for 40 min at 37 C and 250 rpm. The intestinal pieces were washed with harvest buffer (RPMI 1640, 5% FBS, 20 U/ml penicillin, 20 mg/ml streptomycin, 5 mM HEPES and 2 mM L-glutamine), and collagenase solution was added (1 mg/ml collagenase [Sigma-Aldrich], and 100 mg/ml DNase I [Sigma-Aldrich]). The intestinal pieces were incubated for 10 min at 37 C and 250 rpm and were then passed through 18 G and 21 G needles. The entire contents were decanted into a 70 -mm cell strainer in 50-ml conical tubes (BD Falcon, 352350). The flow through was collected, and used for analysis.
Histopathology
Tissues were immersion-fixed in 10% buffered formalin (Wako) and embedded in paraffin blocks. The sections (4 mm thick) were stained with hematoxylin and eosin.
Flow cytometric analysis
Dead cells were excluded from the analysis after 7-aminoactinomycin D staining. After the Fc-receptor was blocked with CD16/32 antibody, the cells were stained with the indicated antibodies. The samples were analysed with the FACSCanto II system (BD Biosciences). The acquired data were analysed with the FlowJo software (version 9.3.1; Tree Star). The 7-aminoactinomycin D was purchased from Wako.
Microscopic analysis
Confocal microscopy was carried out on the Relb-Venus knock-in MEFs or DCs in 8-chambered cover glass slides (Thermo Scientific, 155409) in a humidified CO 2 incubator (37 C, 5% CO 2 ) on an Olympus FV-1000D IX81 with a 20Â phase contrast objective. The excitation of the Venus signal was performed with an argon ion laser at 515 nm. The emitted light was reflected through a 535565-nm bandpass filter from a 560-nm dichroic mirror. The data capture and extraction was carried out with the FV10-ASW software (Olympus).
Results and Discussion
Generation of the Relb-Venus knock-in mice To monitor the dynamic behavior of RelB through the imaging of RelB fused to a fluorescence protein, we first generated an expression vector for RelB-Venus, in which a yellow fluorescence protein, Venus, was fused to the RelB C-terminus region. Although RelBVenus overexpression activated a kB-site driven-luciferase reporter similar to RelB ( Supplementary Fig.  S1 ), the RelB-Venus that was retrovirally expressed in mouse embryonic fibroblast (MEF) cells was not translocated into the nucleus in response to lymphotoxin-b receptor (LTbR) activation, which normally induces nuclear translocation of endogenous RelB ( Supplementary Fig. S2A ). In contrast, retrovirally expressed monomeric red fluorescent protein (mRFP) -RelA, in which mRFP was fused to the RelA N-terminus region in MEF cells, was translocated into the nucleus upon TNFa stimulation like endogenous RelA, as previously reported (13) ( Supplementary  Fig. S2B ). This suggested that the stimulation-dependent nuclear translocation of RelB likely requires tight Relb expression regulation. Therefore, we generated knock-in mice expressing a RelB-Venus fusion protein from the endogenous Relb genomic locus using homologous recombination. Venus cDNA lacking the first ATG followed by the sequence encoding the FLAG epitope was inserted just upstream of the RelB termination codon (Fig. 1A) . The targeting vector also contained a neomycin resistance gene (neo) that was driven by the mouse phosphoglucokinase (PGK) gene promoter, which was flanked by loxP sites, and a diphtheria toxin A fragment gene (DT-A) to correctly select targeted homologous recombinant embryonic stem (ES) cell clones. Southern blot analysis revealed that the ES cell clones with one correctly targeted Relb allele were obtained (Fig. 1B ). The resulting clones were then injected into blastocysts using standard techniques, and germline transmission was obtained after crossing the resulting chimaeras with C57BL/6 mice. However, the mice with the one correctly targeted Relb allele (Relb Targeted/+ , Fig. 1C ) did not express a detectable RelB-Venus protein level (data not shown). Therefore, the mice were further crossed with CAGCre transgenic mice (14) , in which Cre recombinase is ubiquitously expressed, to remove the neo expression cassette because its insertion often inhibits target gene expression (15) . The resulting mice that did not have the neo expression cassette (Relb Venus/+ ) were crossed to generate Relb Venus/Venus (Relb-Venus knock-in) mice (Fig. 1D) . The Relb Venus/Venus mice expressed the RelBVenus protein, whose expression levels in various organs were similar to the RelB protein expression levels that are observed in wild-type mice (Fig. 1E) , confirming that RelB-Venus expression regulation was similar to that of RelB expression.
The abnormal structures that are observed in the lymphoid organs of Relb / mice were absent in the Relb-Venus knock-in mice To analyse the dynamic behavior of RelB at the singlecell level with the Relb Venus/Venus mice, the following two points must be confirmed. First, RelB-Venus is functionally equivalent to RelB. Second, RelB-Venus expression in cells derived from the Relb Venus/Venus mice is sufficiently visible by confocal fluorescence microscopy. The Relb Venus/Venus mice appeared normal and were born in expected Mendelian ratios (data not shown). Although the Relb / mice displayed reduced weight gain, thymic atrophy and splenomegaly, the Relb Venus/Venus mice did not show such abnormalities ( Fig. 2A) . Histologic analysis revealed that the Relb Venus/Venus mice had structurally normal thymi and spleens and that the Relb / mice displayed defective medullary thymic epithelial cell development and lacked red pulp in the spleen (Fig. 2B) . Given that these defects were due to impaired RelB target gene expression, these results strongly suggest that the RelB-Venus fusion protein regulates gene expression with similar efficiency and specificity to that of wildtype RelB.
Nuclear translocation of the RelB-Venus fusion protein upon activation of the non-canonical pathway was similar to wild-type RelB To further confirm that the RelB-Venus was functionally equivalent to RelB, their stimulation-dependent nuclear translocation was analysed in SV40 large T antigen-immortalized MEF cells that were derived from the Relb Venus/Venus and wild-type mice. After the cells were stimulated with an agonistic anti-LTbR monoclonal antibody (mAb), their cytoplasmic and nuclear fractions were prepared and subjected to western blotting. Because LTbR activates the non-canonical pathway, a significant amount of wild-type RelB was translocated to the nucleus with concomitant processing of p100 to p52, which was also translocated to the nucleus and formed a heterodimer with RelB (Fig.  3A) . With similar kinetics, RelB-Venus was clearly translocated to the nucleus in response to the antiLTbR mAb stimulation (Fig. 3A) . In contrast, neither RelB-Venus nor wild-type RelB were translocated to the nucleus in response to TNFa stimulation, whereas nuclear RelA translocation and degradation of IkBa were observed (Fig. 3B) . These results, together with the thymus and spleen histological analysis (Fig. 2) , indicated that RelB-Venus and RelB were functionally indistinguishable. Moreover, RelB-Venus was easily detectable with confocal fluorescence microscopy, and the nuclear translocation of RelB-Venus in response to the stimulation by anti-LTbR mAb or TNF-like weak inducer of apoptosis (TWEAK), a ligand for Fn14, was clearly observed, but not upon TNFa stimulation (Fig. 3C) .
Identification of the RelB low population as a possible novel intermediate cDC maturation stage RelB is highly expressed in thymic DCs (16) and a lack of RelB resulted in impaired DC generation, which included reduced thymic DC numbers and defective CD8a DC differentiation in the spleen. Moreover, the LPS stimulation-induced upregulation of costimulatory molecules and the cross-priming T cell activation ability were abrogated in Relb / DCs (17, 18) . Therefore, RelB is a critical transcription factor for (Fig. 4B, upper panel) . Because MHC II and co-stimulatory molecule expression increases with cDC maturation, the MHC II and co-stimulatory molecule (including CD86 and CD40) cell surface expression levels in the two populations and the RelB-Venus cells were analysed. The RelBVenus high cDCs showed higher expression levels of these cell surface markers than the RelB-Venus low cDCs, whereas the RelB-Venus cDCs showed the lowest expression levels of these maturation markers (Fig. 4B, lower panels) . Therefore, we speculated that the cDC maturation stages could develop with increasing amounts of RelB expression. To acquire evidence that supports this speculation, we first measured side-scattered light (SSC) of the three populations because SSC is proportional to the complexity of the plasma membrane and intracellular structure, which increases during DC maturation. The SSC increased with the increasing RelB expression levels (Fig. 4C) . To further confirm this speculation, the RelBVenus + cDCs were next sorted from the cDC fraction and analysed for RelB-Venus expression and cell morphology to determine the cDC maturation stage using confocal microscopy. Although the RelB-Venus in the RelB-Venus low cells was mostly localized in the cytoplasm, the RelB-Venus was localized in the nuclei of the RelB-Venus high cells (Fig. 4D) , indicating that the RelB-Venus was possibly activated by the noncanonical pathway in the RelB-Venus high cDCs. Interestingly, the RelB-Venus high cDCs grew branched projections, which is a typical characteristic of mature DCs, whereas the RelB-Venus low and RelB-Venus cDCs showed similar morphology and barely grew any projections (Fig. 4D , Bright-field). Because the RelB-Venus expression levels were mostly equivalent to those of endogenous RelB, these results indicated that the RelB high thymic cDCs, which constitute approximately 14% of the total thymic cDCs (70% of RelB-Venus + cDCs, which is 20% of total thymic cDCs), were in the mature stage, whereas the RelB cDCs were in the immature stage. Moreover, based on their cell shape and co-stimulatory molecule surface expression, the RelB low cDC population was likely to be a novel intermediate maturation stage.
Similar analysis of the thymic pDCs revealed that approximately 14% of the pDCs were RelB-Venus + (Fig. 4E, a red rectangle in the lower-right panel) , whereas approximately 83% of the pDCs were RelB-Venus (Fig. 4E , a blue rectangle in the lowerright panel). Although the RelB-Venus expression levels in the RelB-Venus + pDCs were significantly lower than those in the RelB-Venus + cDCs (data not shown), the RelB-Venus + pDCs showed higher MHC II and the co-stimulatory molecule expression levels, including CD86 and CD40, than the RelB-Venus pDCs (Fig. 4F) . Because the low RelB-Venus MEFs were stimulated with TNFa (10 ng/ml) for the indicated times. Cytoplasmic and nuclear lysates were prepared and analysed by western blotting. (C) Relb Venus/Venus MEFs were unstimulated or stimulated with a-LTbR mAb (0.3 mg/ml), TWEAK (6 ng/ml) or TNFa (10 ng/ml) for 12 hr and subcellular localization of RelB-Venus protein was analysed by confocal microscopy. Scale bars, 50 mm. All data are representative of three independent experiments. expression level hampered the confocal analysis of the RelB-Venus + pDCs, we were unable to judge the relationship between the RelB expression and the pDC maturation stage through their morphology. However, the higher MHC II and the co-stimulatory molecule expression levels suggested that the RelB + pDC population likely included intermediate and full pDC maturation stages.
The splenic cDCs were analysed next. Approximately 60% of the splenic cDCs were RelBVenus + (Fig. 5A , a red rectangle in the lower-right panel), whereas approximately 40% of the splenic cDCs were RelB-Venus (Fig. 5A , a blue rectangle in the lower-right panel). In contrast to thymic cDCs, no significant difference in MHC II and the co-stimulatory molecule expression levels were observed between the RelB-Venus + and RelBVenus cDCs (Fig. 5B) . However, when the RelBVenus + cDCs were sorted from the cDC fraction and analysed for RelB-Venus expression and cell morphology to monitor the cDC maturation stage with confocal microscopy, approximately 6% were RelB-Venus high cDCs that showed nuclear localization of RelB-Venus and grew branched projections. In contrast, the RelB-Venus low cDCs, in which RelB-Venus was mostly observed in the cytoplasm, and RelBVenus cDCs showed similar morphology and barely grew projections (Fig. 5C ). These results indicate that the RelB high splenic cDCs, which constitute approximately 4% of the total splenic cDCs (6% of RelBVenus + cDCs, which is 60% of total splenic cDCs), were in the mature stage and that the RelB cDCs were in the immature stage. Similar to thymic cDCs, based on their cell shape and co-stimulatory molecule surface expression, the RelB low splenic cDC population is likely a novel intermediate maturation stage. The CD8a expression was significantly lower in the RelB + cDCs than in the RelB cDCs, which is consistent with the findings of a previous report demonstrating that a lack of RelB blocks CD8a cDC differentiation but not CD8a + cDC differentiation (12) .
A similar analysis of the splenic pDCs revealed that approximately 10% of pDCs were RelB-Venus + (Fig.  5D , a red rectangle in the lower-right panel) and that approximately 90% were RelB-Venus (Fig. 5D , a blue rectangle in the lower-right panel). However, no significant MHC II or co-stimulatory molecule expression differences between the RelB-Venus + and RelBVenus pDCs were observed (Fig. 5E ). Because the relatively low RelB-Venus expression hampered the RelB + pDC confocal analysis, the relationship between RelB expression and the splenic pDC differentiation stage was not clear.
RelB is highly expressed in CD103
low intestinal DCs DCs are present in the lamina propria (LP) of the small and large intestine and in the gut-associated lymphoid tissue (GALT), including the isolated lymphoid follicles, Peyer's patches (PP) and the mesenteric lymph nodes (MLN) (21, 22) . It was reported that RelB plays a crucial role in the colon LP DCs (23) . Therefore, the relationship between RelB expression and the colonic DC maturation stage is of interest. DCs were extracted from colons and analysed for RelB-Venus and various surface antigen expression levels. Approximately 9% of the colonic CD11b CD11c + DCs (R1 population) were RelB-Venus + (Fig. 6A , a red rectangle in the lower-middle panel), whereas approximately 90% were RelB-Venus (Fig. 6A , a blue rectangle in the lower-middle panel). The RelB-Venus + DCs showed slightly higher MHC II and CD86 expression levels than the RelB-Venus DCs (Fig. 6B) . In contrast, CD103 expression was significantly lower in the RelB-Venus + DCs than in the RelB-Venus DCs (Fig. 6B) . Next, the RelB-Venus + DCs were sorted and analysed for RelB-Venus expression and cell morphology to evaluate the DC differentiation stage with confocal microscopy. Approximately 18% were RelB-Venus high DCs and showed nuclear RelB-Venus localization, whereas the RelB-Venus low DCs mostly showed cytoplasmic RelB-Venus localization (Fig.  6C) . Although the RelB-Venus high DCs, like RelBVenus low and RelB-Venus DCs, barely grew projections, which is inconsistent with thymic and splenic DCs, the nuclear RelB-Venus localization suggested that the RelB high colonic DCs in the colon LP could be very close to the mature stage and that the RelB low colonic DC population could be an intermediate maturation stage DC. It was recently reported that the TLR-mediated RIP3K-dependent activation of RelB induces cytokine expression in colonic DCs, thereby playing a critical role in tissue repair (23) . Therefore, the RelB high colonic DCs that were identified in this study could be involved in tissue repair and required for the maintenance of healthy colon homeostasis.
In this study, we have established an experimental system that allows us to analyse the relationship between the DC maturation stage and RelB expression and activation, which is a major NF-kB subunit that can be activated by the non-canonical pathway, at the single-cell level by generating Relb-Venus knock-in mice. Another notable application of the Relb-Venus knockin mice is to monitor the dynamic regulation of the non-canonical NF-kB pathway in primary cells at the single-cell level. In the canonical pathway, the combined action of various positive and negative regulation signals from NF-kB activation results in an oscillation of the RelA nuclear concentrations in response to various extracellular stimulations (2427). This oscillation is crucial for the appropriate NF-kB-dependent transcription levels and durations, which thereby adequately controls the functions of various cell types of cell (2831). The Relb-Venus knock-in mice could allow us to uncover novel dynamic regulations of non-canonical pathway regulation types that are relevant to various cell functions, which may thereby opening a new field that links the dynamic behavior of this transcription factor to the regulation of its transcriptional activity.
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